Pharvaris director plans sale of 14,493 shares

Rhea-AI Filing Summary

Pharvaris N.V. (PHVS) director Robert Howard Glassman filed a Rule 144 notice indicating an intention to sell up to 14,493 shares of Pharvaris common stock through Morgan Stanley Smith Barney LLC on September 17, 2026. The shares relate to a stock option exercise with cash payment.

The notice also lists prior sales by Robert Glassman over the preceding three months, including 8,667 and 8,000 Pharvaris common shares sold on September 15 and September 9, 2026, respectively.

Key Figures

Shares proposed for sale: 14,493 shares Aggregate market value of proposed sale: $558,812.40 Shares sold on September 15, 2026: 8,667 shares +3 more

6 metrics

Shares proposed for sale 14,493 shares Maximum Pharvaris common shares in the Rule 144 notice for September 17, 2026

Aggregate market value of proposed sale $558,812.40 Associated with the 14,493 Pharvaris common shares in the Rule 144 filing

Shares sold on September 15, 2026 8,667 shares Pharvaris common stock sold by Robert Glassman during the past three months

Proceeds from September 15, 2026 sale $331,716.42 Aggregate proceeds from 8,667 Pharvaris common shares sold

Shares sold on September 9, 2026 8,000 shares Pharvaris common stock sold by Robert R. Glassman during the past three months

Proceeds from September 9, 2026 sale $300,396.00 Aggregate proceeds from 8,000 Pharvaris common shares sold

Key Terms

Rule 144, Stock Option Exercise, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 09/17/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 14493 | 558812.40"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Pharvaris N.V. (PHVS)?

The filing discloses that director Robert Howard Glassman filed a Rule 144 notice to sell up to 14,493 Pharvaris common shares on September 17, 2026 following a stock option exercise, using Morgan Stanley Smith Barney LLC as the broker.

How many Pharvaris (PHVS) shares are proposed to be sold under this Rule 144 notice?

The notice states an intention to sell up to 14,493 shares of Pharvaris N.V. common stock. The filing lists an aggregate market value of $558,812.40 associated with these shares as part of the Rule 144 disclosure.

Which broker is handling the planned sale for Pharvaris (PHVS) shares?

The Rule 144 notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, as the broker for the proposed sale of 14,493 Pharvaris common shares on September 17, 2026.

What prior Pharvaris (PHVS) share sales by Robert Glassman are disclosed?

The filing lists prior sales over the past three months: 8,667 shares of Pharvaris common stock sold on September 15, 2026 for $331,716.42, and 8,000 shares sold on September 9, 2026 for $300,396.00.

What is the nature of the Pharvaris (PHVS) shares to be sold in this Form 144?

The shares to be sold are Pharvaris N.V. common stock acquired via a stock option exercise from the issuer, with the filing noting the nature of payment as cash and a planned sale date of September 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:20 PM Accepted by SEC EDGAR 09/17/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001897890
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PHARVARIS N.V.
SEC File Number	001-40010
Address of Issuer	Emmy Noetherweg 2 Leiden NETHERLANDS 2333 BK
Phone	31 (0)71 2036 410
Name of Person for Whose Account the Securities are To Be Sold	ROBERT GLASSMAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	14493	558812.40	70204506	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2026	Stock Option Exercise	Issuer			14493	09/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROBERT GLASSMAN Emmy Noetherweg 2 Leiden P7 2333 BK	Common	09/15/2026	8667	331716.42
ROBERT R. GLASSMAN Emmy Noetherweg 2 Leiden P7 2333 BK	Common	09/09/2026	8000	300396.00

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Robert Howard Glassman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)